UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's disease, ...

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...